Home › Compare › BIBLF vs ABBV
BIBLF yields 3.08% · ABBV yields 3.06%● Live data
📍 BIBLF pulled ahead of the other in Year 3
Combined, BIBLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BIBLF + ABBV for your $10,000?
Waterloo Brewing Ltd. engages in the production, distribution, and sale of alcohol-based products. It produces, sells, markets, and distributes bottled, canned, and draft premium beer under the Waterloo brand name; and value beer under the Laker and Red Cap brands. The company also produces, sells, and markets vodka-based coolers and ciders under the Seagram trademark; beer under the LandShark brand name; and coolers under the Margaritaville trademark. In addition, it produces, sells, markets, and distributes various beer products under the licensed PC trademark; and produces various products under the No Name brand. Further, the company engages in producing and packaging beer and ready-to-drink alcoholic beverages for other customers. It distributes products to end consumers primarily through grocery stores, The Beer Store in Ontario, and Provincial Liquor Boards in Canada. The company was formerly known as Brick Brewing Co. Limited and changed its name to Waterloo Brewing Ltd. in June 2019. Waterloo Brewing Ltd. was incorporated in 1984 and is headquartered in Kitchener, Ontario.
Full BIBLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.